CHRNA5 Antibody - #DF6586

Fig. 3. Nicotine downregulates JWA expression via CHRNA5/AKT signaling in LUAD cells. A The mRNA expression of the 12 nicotinic acetylcholine receptors from the GSE19804 dataset, which includes 60 LUAD tissues (Tumor) and their pared adjacent normal tissues (Normal). B The mRNA expression of the 12 nicotinic acetylcholine receptors in Never smoker with lung cancer and Current smoker with lung cancer in the GSE68465 dataset. C, D GSEA plot showed that MUELLER_PLURINET pathway was enriched in higher expression of CHRNA5 (C) and not in higher expression of CHRNA9 (D) in the GSE68465 dataset. The samples were divided into high and low groups according to gene expression (median). E Western blotting analysis showing the protein level of CHRNA5 in lung cancer cell lines and corresponding human bronchial epithelial (HBE) cells. F Pearson correlation analysis showing strong negative correlation between JWA and CHRNA5 based on CCLE, TCGA-LUAD, TCGA-LUSC and CPTAC-LUSC datasets. G, H Western blotting analysis showing the protein level of CHRNA5, CD44 and SOX2 in A549 (G) and NCI-H1975 cells (H) upon exposure to different concentrations of nicotine. I Western blotting analysis showing the protein level of JWA, CD44 and SOX2 in A549 and NCI-H1975 cells upon silencing CHRAN5. J Tumor sphere formation assay of A549 cells transfected with siRNA or siCHRNA5. Representative spheres were shown and quantified. Scale bar: 50 µm. Data were presented as means ± SD, ns non-significant, *P